|                         |     |      |                     |         |                     | 0 1     |                     |         |
|-------------------------|-----|------|---------------------|---------|---------------------|---------|---------------------|---------|
| Treatment groups        | No. | %    | 5-year OS (95%CI)   | P value | 5-year PFS (95%CI)  | P value | 5-year DMFS (95%CI) | P value |
|                         |     |      |                     | <0.001  |                     | <0.001  |                     | <0.001  |
| Low-risk group          | 603 | 33.2 | 95.9% (94.3%-97.5%) |         | 95.9% (94.3%-97.5%) |         | 95.4% (93.6%-97.2%) |         |
| Intermediate-risk group | 559 | 30.8 | 89.2% (86.7%-91.7%) |         | 88.7% (86.0%-91.4%) |         | 88.8% (86.1%-91.5%) |         |
| High-risk group         | 652 | 36.0 | 75.8% (72.5%-79.1%) |         | 73.3% (69.8%-76.8%) |         | 76.4% (73.1%-79.7%) |         |

## Appendix table 1. Comparison of cumulative survival rates of patients in different risk groups.

Abbreviations: **OS** =overall survival; **PFS** =progression-free survival; **DMFS** =distant metastasis-free survival